FDA
-
-
-
-
-
-
-
Medincell: The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults
-
-
-
-
-
-
-
Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizo
-
-
-
-
-
-
-
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New
-
-
-
-
-
-
-
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
-
-
-
-
-
-
-
Goldman Sachs Reiterates Buy Rating on Teva Pharma (TEVA)
-
-
-
-
-
-
-
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
-
-
-
-
-
-
-
Lexaria Bioscience (LEXX): Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
-
323,577 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

